NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.
NeuroDerm Announces Second Quarter 2016 Financial Results and Provides Corporate Update
Company to host conference call and webcast today at 8:30 a.m. ET.> Read More
NeuroDerm Initiates Patient Enrollment in a Phase III Trial of ND0612L for the Treatment of Parkinson’s Disease
Number of patients targeted for enrollment reduced based on observed and anticipated treatment effect > Read More
NeuroDerm to Host Second Quarter 2016 Financial Results Conference Call on August 25, 2016
Company will report financial results for the second quarter of 2016 before the market opens on Thursday, August 25, 2016. Management will host a conference call beginning at 8:30 a.m. Eastern Time that day to review results and provide a company update.”> Read More